Glycotoxines, carbonyl stress and relevance to diabetes and its complications

Physiological Research

Volumn 59, Issue 2, 2010, Pages 147-156

  Turk, Z ^a  

^a University of Zagreb   (Croatia)

Author keywords

3 deoxyglucosone; Advanced glycation end product; Carbonyl stress; Diabetes; Glyoxal; Methylglyoxal

Indexed keywords

ADVANCED GLYCATION END PRODUCT; METHYLGLYOXAL;

DIABETES MELLITUS; HUMAN; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; REVIEW;

DIABETES COMPLICATIONS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS; PYRUVALDEHYDE;

EID: 77953934812     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Ahmed N, Thornalley J: Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 9: 233-245, 2007
2. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ: Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48: 1590-1603, 2005.
3. Baynes JW, Thorpe SR: Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28: 1708-1716, 2000.
4. Beisswenger PJ, Howell SK, O'dell RM, Wood ME, Touchette AD, Szwergold BS: α-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24: 726-732, 2001.
5. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS: alpha-Oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 31: 1358-1363, 2003a.
6. Beisswenger PJ, Howell SK, Smith K, Szwergold BS: Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim Biophys Acta 1637: 98-106, 2003b.
7. Beisswenger BG, Delucia EM, Lapoint N, Sanford, RJ, beisswenger PJ: Ketosis leads to increased methylglyoxal production on the Atkins diet. Ann NY Acad Sci 1043: 201-210, 2005a.
8. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, MAUER M: Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 54: 3274-3281, 2005b.
9. Bourrajjaj M, Stehouwer CDA, Van Hinsbergh VWM, Schalkwijk CG: Role of methylglyoxal adducts in the development of vascular complications in diabetes mellitus. Biochem Soc Trans 31: 1400-1402, 2003.
10. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
11. Brownlee M: The pathobiology of diabetic complications - a unifying mechanism. Diabetes 54: 1615-1625, 2005.
12. Chang T, Wu L: methylglyoxal, oxidative stress, and hypertension. Can J Physiol Pharmacol 84: 1229-1238, 2006.
13. Chellan P, Nagaraj RH: Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch Biochem Biophys 368: 98-104, 1999.
14. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, de blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108: 1070-1077, 2003.
15. DCCT (Diabetes Control and Complications Trial Research Group): Effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
16. Finot PA: Nonenzymatic browning products: physiologic effects and metabolic transit in relation to chemical structure. Diabetes 31 (Suppl 3): 22-28, 1982.
17. Frye EB, Degenhardt TP, Thorpe SR, Baynes JW: Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 273: 18714-18719, 1998.
18. Gaens KH, Van der Kallen CJ, Van Greevenbroek MM, Feskens EJ, Stehouwer CD, Schalkwijk CG: Receptor for advanced glycation end product polymorphisms and type 2 diabetes: the CODAM study. Ann NY Acad Sci 1126: 162-165, 2008.
19. Genuth S, Lipps J, Lorenzi G, Nathan DM, Davis MD, Lachin JM, Cleary PA: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287: 2563-2569, 2002.
20. Hamada Y, Nakamura J, Fujisawa H, Yago H, Nakashima E, Koh N, Hotta N: Effects of glycemic control on plasma 3-deoxyglucosone levels in NIDDM patients. Diabetes Care 20: 1466-1469, 1997.
21. Han Y, Randell E, Vasdev S, Gill V, Gadag V, Newhook LA: Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with type 1 diabetes. Mol Cell Biochem 305: 123-131, 2007.
22. Huebschmann G, Regensteiner JG, Vlassara H, Reusch JE: Diabetes and advanced glycoxidation end products. Diabetes Care 29: 1420-1432, 2006.
23. Ihnat MA, Thorpe JE, Ceriello A: Hypothesis: the 'metabolic memory', the new challenge of diabetes. Diabet Med 24: 582-586, 2007.
24. Jono T, Nagai R, Lin X, Ahmed N, Thornalley PJ, Takeya M, Horiuchi S: N-epsilon-(carboxymethyl)lysine and 3-DG-imidazolone are major AGE structures in protein modification by 3-deoxyglucosone. J Biochem 136: 351-358, 2004.
25. Kalapos MP: On the mammalian acetone metabolism: from chemistry to clinical implications. Biochim Biophys Acta 1621: 122-139, 2003.
26. Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Shi Du Yan S, D'agati V, Naka YU, Ramasamy R, Herold K, Yan SF, Schmidt AM: Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann N Y Acad Sci 1043: 553-561, 2005.
27. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, HEITMANN K, VLASSARA H: Orally absorbed reactive glycation products (glycotoxins) - an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94: 6474-6479, 1997.
28. LAL S, Szwergold BS, Taylor AH, Randall WC, Kappler F, Wells-Knecht KJ: Metabolism of fructose-3-phoshate in the diabetic rat lens. Arch Biochem Biophys 318: 191-199, 1995.
29. Lal S, Randall WC, Taylor AH, Kappler F, Walker M, Brown TR, Szwergold BS: Fructose-3-phosphate production and polyol pathway metabolism in diabetic rat hearts. Metabolism 46: 1333-1338, 1997.
30. Lapolla A, Flamini R, Vedova AD, Senesi A, Reitano R, Fedele D: Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin Chem Lab Med 41: 1166-1173, 2003.
31. Lo TWC, Westwood ME, Mclellan AC, Selwood T, Thornalley PJ: Binding and modification of proteins by methylglyoxal under physiological conditions - a kinetic and mechanistic study with N-alpha-acetylarginine, N-alpha-acetylcysteine, and N-alpha-acetyllysine, and bovine serum albumin. J Biol Chem 269: 32299-32305, 1994.
32. Lukic IK, Humpert PM, Nawroth PP, Bierhaus A: The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann NY Acad Sci. 1126: 76-80, 2008.
33. Lyles GA, Chalmers J: The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem Pharmacol 43: 1409-1414, 1992.
34. Maillard LC: Action des acides aminés sur les sucres: formation des mélanoïdines par voie méthodique. Réaction de Maillard. C R Acad Sci 154: 66-68, 1912.
35. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343: 1519-1522, 1994.
36. McLellan AC, Thornalley PJ, Benn J, Sonksen PH: Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 87: 21-29, 1994.
37. Misur I, Zarkovic K, Barada A, Batelja L, Milicevic Z, Turk Z: Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy. Acta Diabetol 41: 158-166, 2004.
38. Monnier VM, Sell DR, Genuth S: Glycation products as markers and predictors of the progression of diabetic complications. Ann NY Acad Sci 1043: 567-581, 2005.
39. Nagaraj RH, Sady C: The presence of a glucose-derived Maillard reaction product in the human lens. FEBS Lett 382: 234-238, 1996.
40. Nakajima K, Ohta K, Mostefaoui TA, Chai W, Utsukihara T, Horiuchi CA, Murakami M: Glyoxal sample preparation for high-performance liquid chromatographic detection of 2,4-dinitrophenylhydrazone derivative: suppression of polymerization and mono-derivative formation by using methanol medium. J Chromatogr A 1161: 338-341, 2007.
41. Nemet I, Turk Z, Duvnjak L, Car N, Varga-Deftardarovic L: Humoral methylglyoxal level reflects glycemic fluctuation. Clin Biochem 38: 379-383, 2005.
42. Nemet I, Varga-Deftardarovic L, Turk Z: Methylglyoxal in food and living organisms. Mol Nutr Food Res 50: 1105-1117, 2006.
43. Niwa T: 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J Chromatogr B 731: 23-36, 1999.
44. Niwa T, Takeda N, Miyazaki T, Yoshizumi H, Tatematsu A, Maeda K. Elevated serum levels of 3-deoxyglucosene, a potent protein-cross-linking intermediate of the Maillard reaction, in uremic patients. Nephron 69: 438-443, 1995.
45. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99: 1272-1280, 1997.
46. Niwa T, Takeda N, Yoshizumi H, Tatematsu A, Ohara M, Tomiyama S, Odani H, Shinzato T, Matsumoto Y, Usami J, Maeda K: Increase in three alpha, beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 256: 89-93, 1999.
47. Pokupec R, Kalauz M, Turk N, Turk Z: Advanced glycation endproducts in human diabetic and non-diabetic cataractous lenses. Graefes Arch Clin Exp Ophthalmol 241: 378-384, 2003.
48. Rabbani N, Sebekova K, Sebekova K JR, Heidland A, Thornalley PJ: Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney Int 72: 1113-1121, 2007.
49. Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM: Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann NY Acad Sci 1126: 7-13, 2008.
50. Richard JP: Mechanism for the formation of methylglyoxal from triosephosphates. Biochem Soc Trans 21: 549-553, 1993.
51. Sady C, Jiang CL, Chellan P, Madhun Z, Duve Y, Glomb MA, Nagaraj RH: Maillard reactions by α-oxoaldehydes: detection of glyoxal-modified proteins. Biochim Biophys Acta 1481: 255-264, 2000.
52. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products - a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84: 489-497, 1999.
53. Shamsi FA, Nagaraj RH: Immunochemical detection of dicarbonyl-derived imidazolium protein crosslinks in human lenses. Curr Eye Res 19: 276-284, 1999.
54. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 44: 129-146, 2001.
55. Thornalley PJ: The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 269: 1-11, 1990.
56. Thornalley PJ: Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 111-112: 137-151, 1998.
57. Thornalley PJ: Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31: 1343-1348, 2003.
58. Thornalley PJ: Dicarbonyl intermediates in the Maillard reaction. Ann NY Acad Sci 1043: 111-117, 2005.
59. Thorpe SR, Baynes JW: Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25: 275-281, 2003.
60. Thorpe SR, Lyons TJ, Baynes JW: Glycation and glycoxidation in diabetic vascular disease. In: Oxidative Stress and Vascular Disease. KEANEY JF, (ed) Kluwer Academic Publishers, Norwell, MA, 2000, pp 259-285.
61. Tressel T, Thompson R, Zieske LR, Menendez MITS, Davis L: Interaction between L-threonine dehydrogenase and aminoacetone synthetase and mechanism of aminoacetone production. J Biol Chem 261: 16428-16437, 1986.
62. Tsukushi S, Katsuzaki T, Aoyama I, Takayama F, Miyazaki T, Shimokata K, Niwa T: Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. Kidney Int 55: 1970-1976, 1999.
63. Turk Z: Advanced glycation toxicity in diabetic complications. Diabetol Croat 26: 11-26, 1997.
64. Turk Z: Glycation and complications of diabetes. Diabetol Croat 30: 49-54, 2001.
65. Turk Z, Ljubic S, Turk N, Benko B: Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta 303: 105-111, 2001.
66. Turk Z, Šesto M, Skodlar J, Ferenčak G, Pokupec R, Turk N, Stavljenic-RUKAVINA A: The products of advanced glycation in patients with type 2 diabetes and vascular disease. Ann Clin Biochem 40: 552-559, 2003.
67. Turk N, Mornar A, Mrzljak V, Turk Z: Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes with various stages of proteinuria. Diabete Metab 30: 187-192, 2004.
68. Turk Z, Nemet I, Varga-Deftardarovic L, Car N: Elevated level of methylglyoxal during diabetic ketoacidosis and its recovery phase. Diabete Metab 32: 176-180, 2006.
69. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, Baliga S, Vassalotti JA, Vlassara H: Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 42: 532-538, 2003.
70. Wang X, Desai K, Clausen JT, Wu L: Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 66: 2315-2321, 2004.
71. Wang X, Desai K, Chang T, Wu L: Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 23: 1565-1573, 2005.
72. Wang Y, Vom Hagen F, Pfister F, Bierhaus A, Feng Y, Gans R, Hammes HP: Receptor for advanced glycation end product expression in experimental diabetic retinopathy. Ann NY Acad Sci 1126: 42-45, 2008.
73. Wells-Knecht KJ, Lyons TJ, McCance DR, Thorpe SR, Feather MS, Baynes JW: 3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes. Diabetes 43: 1152-1156, 1994.
74. Yamamoto H, Watanabe T, Yamamoto Y, Yonekura H, Munesue S, Harashima A, Ooe K, Hossain S, Saito H, Murakami N: RAGE in diabetic nephropathy. Curr Mol Med 7: 752-757, 2007.